London-listed AstraZeneca said on Monday it would make an upfront payment of $1 billion to Daiichi for an experimental drug called DS-1062, which belongs to a newer class of treatments called antibody drug conjugates (ADC).
Subscribe to:
Post Comments (Atom)
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Thirteen tier 2 and 3 cities register higher traffic in December than pre-COVID-19 levels.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment